AbCellera Biologics Inc. (ABCL)

Market Cap	945.90M -9.0%
Revenue (ttm)	35.33M +7.2%
Net Income	-171.68M
EPS	-0.58
Shares Out	299.34M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,395,984
Open	2.940
Previous Close	2.780
Day's Range	2.880 - 3.170
52-Week Range	1.891 - 6.515
Beta	0.84
Analysts	Buy
Price Target	7.75 (+145.25%)
Earnings Date	Feb 24, 2026

About ABCL

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 11, 2020
• Employees: 596
• Stock Exchange: NASDAQ
• Ticker Symbol: ABCL
• Website: https://www.abcellera.com

Financial Performance

In 2024, AbCellera Biologics's revenue was $28.83 million, a decrease of -24.17% compared to the previous year's $38.03 million. Losses were -$162.86 million, 11.2% more than in 2023.

Analyst Summary

According to 5 analysts, the average rating for ABCL stock is "Buy." The 12-month stock price target is $7.75, which is an increase of 145.25% from the latest price.

Price Target

$7.75

(145.25% upside)

Analyst Consensus: Buy